PRHOINSA Appointed Exclusive Distributor in Spain for NATROX® Wound Care

The partnership offers a new therapeutic solution for healthcare professionals who manage chronic wounds

[13 July 2022 – Cambridge, UK] NATROX® Wound Care, a leading provider of topical oxygen therapy for wounds, is pleased to announce PRHOINSA as its new distributor in Spain. The partnership will help meet growing market demand from Spanish healthcare professionals seeking to use the innovative NATROX® Oxygen Wound Therapy to aid patient care.

What is NATROX® O2
NATROX® Oxygen Wound Therapy is designed to help heal patients with chronic, non-healing wounds. Chronic wounds pose a significant problem both on patient quality of life and costs to healthcare systems worldwide1. NATROX® O2 is an innovative, easy-to-use device clinically proven to stimulate healing2. It can be used during any phase of wound healing and works with any standard secondary dressing.

“We’re excited to make NATROX® O2 available in Spain,” said Juan Carlos Herrero, Marketing Director of PRHOINSA. “Everyone deserves the chance to heal. This technology means clinicians can transform lives with something as simple as oxygen.”

David Fernandez, NATROX® Wound Care, meets with the PRHOINSA team in Spain.

Medical professionals throughout Europe—Spain in particular—regularly request access to NATROX® O2. Last month at the EWMA Conference, the NATROX® team received a steady stream of requests from Spanish clinicians seeking to trial the topical oxygen therapy.

“We’re honoured to partner with industry experts like PRHOINSA,” said David Fernandez, Director of Sales for EMEA & LATAM at NATROX® Wound Care. “They have a deep commitment to customer satisfaction and post-sale support. Their approach aligns strongly with our mission to delight customers.”

The partnership between the companies began in June. NATROX® O2 is available now in Spain. Healthcare professionals in Spain can request to learn more about NATROX® O2 directly from PRHOINSA.

References

  1. Gottrup, F. 2020. Portable, practical and effective: clinical benefits of NATROX® topical oxygen therapy. Journal of Wound Care May 2020, 29(5):53.
  2. Serena TE, Bullock NM, Cole W et al. Topical oxygen therapy in the treatment of diabetic foot ulcers: a multicentre, open, randomised controlled trial. J Wound Care 2021; 30: Suppl.5 S7-14.

About Inotec AMD Ltd.
NATROX® Wound Care is an Inotec AMD brand. The specialist wound care company based in Cambridge, England was formed specifically to introduce new technologies to healthcare professionals around the world to promote faster and better healing for patients. The company’s flagship product, NATROX® Oxygen Wound Therapy, is positioned to become integral to global wound care treatment regimes in the coming years. To learn more, visit:  natroxwoundcare.com.

About PRHOINSA
Prhoinsa is a national company specializing in the commercialization of medical technologies in the national hospital market since 2000. With all the necessary accreditations, their team carry out the training, installation and monitoring of all equipment sold. Their marketing is nationwide, and their highly technical service allows them to maintain all the devices sold in perfect condition. Learn more at: www.prhoinsa.es

# # #

Media Contacts:

NATROX® Wound Care
Jane Clark
VP Marketing & Clinical Affairs
marketing@natroxwoundcare.com
+44 (0)1223 661830


PRHOINSA
Alba Manrique Alcanda
Product Manager
a.manrique@prhoinsa.com
+34 699 385 222

PRHoinsa-meeting_Spain-Distributor_April2022_crop